Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham tells Proactive that the company has been given a boost from the Australian Patent Office, which has issued notification of ‘intent to grant’ for the first of Recce’s new Patent Family 4 anti-infectives. The patent covers the 'Process for Preparation of Biologically Active Copolymer' and expires in 2041.
Recce Pharmaceuticals further strengthens market monopoly for anti-infectives
